Overall, these results highlight the challenges of inclusion of rare variant information for clinical risk assessment and generalizability of implementation of ApoC-III inhibition for treating atherosclerotic disease in dyslipidemia. The gene discussed is APOC3; the disease is metabolic syndrome.